LCQ908
Phase 2Small molecule
NovartisLCQ908 is one of 83 small molecule programs targeting Hepatitis C. It is currently in Phase 2.
2
Indications
8
Total Trials
0
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
306 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Zepatier
Merck & Co.Phase 3
Peginterferon Alfa-2
RochePhase 3
Victrelis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
TMC435
Johnson & JohnsonPhase 3
Ombitasvir/paritaprevir/ritonavir
AbbViePhase 3
Peg-Interferon Alfa-2a
Bristol-Myers SquibbPhase 3
Thymalfasin
SSciClone Pharmaceuticals
Phase 3
ABT-333
AbbViePhase 3
Ledipasvir
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertriglyceridemia2 trials
Familial Chylomicronemia Syndrome2 trials
Hepatitis C1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LCQ908. EMBL-EBI & Wellcome Sanger Institute.
- [4]